title: Antibody structure, instability, and formulation.
abstract: The number of therapeutic monoclonal antibody in development has increased tremendously over the last several years and this trend continues. At present there are more than 23 approved antibodies on the US market and an estimated 200 or more are in development. Although antibodies share certain structural similarities, development of commercially viable antibody pharmaceuticals has not been straightforward because of their unique and somewhat unpredictable solution behavior. This article reviews the structure and function of antibodies and the mechanisms of physical and chemical instabilities. Various aspects of formulation development have been examined to identify the critical attributes for the stabilization of antibodies.
authors.affiliation: Pfizer, Inc., Global Biologics, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, USA. wei.2.wang@pfizer.com
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Satish
authors.initials: S
authors.lastname: Singh
authors.forename: David L
authors.initials: DL
authors.lastname: Zeng
authors.forename: Kevin
authors.initials: K
authors.lastname: King
authors.forename: Sandeep
authors.initials: S
authors.lastname: Nema
mesh_terms: D000911:Antibodies, Monoclonal / Q000737:chemistry*; D002626:Chemistry, Pharmaceutical; D004355:Drug Stability; D004356:Drug Storage; D008958:Models, Molecular; D004364:Pharmaceutical Preparations / Q000737:chemistry; D011487:Protein Conformation; D011489:Protein Denaturation; D012995:Solubility; D013678:Technology, Pharmaceutical / Q000379:methods
chemical_list: D000911:Antibodies, Monoclonal; D004364:Pharmaceutical Preparations